Mabpharm Limited reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 82.88 million. Net loss was CNY 291.74 million compared to CNY 184.63 million a year ago.

Basic loss per share from continuing operations was CNY 0.07 compared to CNY 0.04 a year ago. Diluted loss per share from continuing operations was CNY 0.07 compared to CNY 0.04 a year ago.